Combining Meds Is Best

Published Online: Wednesday, March 1, 2006

A combination of therapies for the relief of rheumatoid arthritis (RA) was found to have a greater effect than either therapy alone, as reported in the January 2006 issue of Arthritis & Rheumatism. A 2-year study involved 539 patients who had had active RA for <3 years.

The patients (mean age 52) were divided into 3 groups: one group received methotrexate; another group received injections of adalimumab; and the third group received both treatments. All groups were evaluated at 6, 12, and 24 months.

After 1 year, 62% of those on combination therapy had a 50% improvement in symptoms, compared with 41% of the adalimumab group and 46% of the methotrexate group. At 2 years, nearly half of the patients on combination therapy exhibited major clinical remission—about twice as many as either of the other groups.

Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues